Literature DB >> 12046776

Abnormal uterine bleeding associated with hormonal contraception.

Sarina Schrager1.   

Abstract

Millions of women in the United States use some type of hormonal contraception: combination oral contraceptive pills (OCPs), progestin-only pills, medroxyprogesterone acetate injections, or subdermal levonorgestrel implants. Abnormal uterine bleeding is a common but rarely dangerous side effect of hormonal contraception. It is, however, a major cause for the discontinuation of hormonal contraception and the resultant occurrence of unplanned pregnancy. The evaluation of abnormal uterine bleeding in women who are using hormonal contraception includes an assessment of compliance, a thorough history and complete physical examination to exclude organic causes of bleeding, and a targeted laboratory evaluation. Pregnancy and the misuse of OCPs are frequent causes of abnormal uterine bleeding. Bleeding is common during the first three months of OCP use; counseling and reassurance are adequate during this time period. If bleeding persists beyond three months, it can be treated with supplemental estrogen and/or a nonsteroidal anti-inflammatory drug (NSAID). Other options are to change to an OCP with a higher estrogen content or to a different formulation (i.e., a low-dose OCP containing a different progestin). Management strategies for women with abnormal uterine bleeding who are using progestin-only contraceptive methods include counseling and reassurance, as well as the administration of supplemental estrogen and/or an NSAID during bleeding episodes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12046776

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  8 in total

1.  Oral contraceptive use among women in the military and the general U.S. population.

Authors:  Lindsey Enewold; Louise A Brinton; Katherine A McGlynn; Shelia H Zahm; John F Potter; Kangmin Zhu
Journal:  J Womens Health (Larchmt)       Date:  2010-05       Impact factor: 2.681

2.  Resumption of postpartum sexual activity and menses among HIV-infected women on lifelong antiretroviral treatment compared to HIV-uninfected women in Africa.

Authors:  Sufia Dadabhai; Bonus Makanani; Nan Hua; Rachel Kawalazira; Frank Taulo; Luis Gadama; Taha E Taha
Journal:  Int J Gynaecol Obstet       Date:  2020-03-02       Impact factor: 3.561

3.  Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.

Authors:  Inka Wiegratz; Susana Bassol; Edith Weisberg; Uwe Mellinger; Martin Merz
Journal:  Reprod Sci       Date:  2014-04-30       Impact factor: 3.060

4.  Endometrial histology of Depomedroxyprogesterone acetate users: a pilot study.

Authors:  Andrea Ries Thurman; David E Soper
Journal:  Infect Dis Obstet Gynecol       Date:  2006

5.  Progestins Upregulate FKBP51 Expression in Human Endometrial Stromal Cells to Induce Functional Progesterone and Glucocorticoid Withdrawal: Implications for Contraceptive- Associated Abnormal Uterine Bleeding.

Authors:  Ozlem Guzeloglu Kayisli; Umit A Kayisli; Murat Basar; Nihan Semerci; Frederick Schatz; Charles J Lockwood
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

Review 6.  Bioactive secondary metabolites in Paris polyphylla Sm. and their biological activities: A review.

Authors:  Chandra Bahadur Thapa; Mukti Ram Paudel; Hari Data Bhattarai; Krishna Kumar Pant; Hari Prasad Devkota; Yagya Prasad Adhikari; Bijaya Pant
Journal:  Heliyon       Date:  2022-02-17

Review 7.  Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview.

Authors:  David F Archer; Diana Mansour; Jean-Michel Foidart
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

8.  Assessment of quality of life and effect of non-pharmacological management in dysmenorrhea.

Authors:  Habeeb Unnisa; Prathiba Annam; Naga Chandrika Gubba; Anees Begum; Keerthi Thatikonda
Journal:  Ann Med Surg (Lond)       Date:  2022-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.